Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interleukin 2 low dose - Beijing ShuangLu Pharmaceutical/Peking University

Next Previous
Search
Drug Profile

Interleukin 2 low dose - Beijing ShuangLu Pharmaceutical/Peking University

Alternative Names: hrIL-2; Recombinant human IL-2

Latest Information Update: 28 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing ShuangLu Pharmaceutical; Peking University
  • Developer Beijing ShuangLu Pharmaceutical; Monash University; Peking University
  • Class Adjuvants; Antineoplastics; Immunotherapies; Interleukins; Lymphokines
  • Mechanism of Action Interleukin 2 receptor agonists; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Sjogren's syndrome; Systemic lupus erythematosus

Most Recent Events

  • 31 Mar 2021 No development reported - Phase-II for Sjogren's syndrome in China (SC)
  • 21 Jan 2020 Peking University People's Hospital plans a phase II trial for Idiopathic inflammatory myopathy in January 2020 (NCT04237987)
  • 05 Sep 2018 Interleukin 2 low dose is still in phase II trials for Sjogren's syndrome in China

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top